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The recent availability of molecular targeted therapies leads to a reconsideration of the treatment strategy for
patients with distant metastases from medullary thyroid carcinoma. In patients with progressive disease, treatment
with kinase inhibitors should be offered.
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INTRODUCTION
Medullary thyroid carcinoma (MTC) accounts for 5–8% of
all thyroid cancers (1,2). Distant metastases are observed at
presentation in 7–23% of MTC patients. In patients with
elevated calcitonin levels after initial treatment, clinical
recurrence will occur at different time intervals after
surgery, depending on the amount of persistent disease
and the progression rate. Recurrent disease in the neck and
mediastinum is frequently amenable to surgery, and some
patients may also benefit from external radiation therapy.
Distant metastases are the main cause of MTC-related death.
They often affect multiple organs, including lungs, bones,
and liver, and more rarely brain, skin, and breast, and they
are frequently associated with a neck recurrence (3). In
patients with recurrent disease, a good quality of life is
usually maintained, but diarrhea may be debilitating. Slow
tumor growth is common and, in retrospective series,
survival after the discovery of distant metastases was
around 25% at 5 years and 10% at 10 years, but recent
series suggest that survival rates might be higher with
earlier discovery of metastatic disease.
Selection of patients for clinical trials
Patients with metastatic MTC must be accurately char-
acterized concerning all clinical prognostic indicators,
including age, performance status, histology, disease extent
and location, and progression rate. The importance of this
latter parameter cannot be overemphasized, as many
patients with metastatic MTC can be asymptomatically
stable for long periods of time, and in such patients, the
benefits of novel therapies may be largely outweighed by
drug toxicities and the rigors of clinical trial participation.
Also, there is no evidence that the efficacy of these novel
therapies is higher at an early stage than later when
metastases are larger in size, and treatment can be
postponed in most patients until progression has been
documented by imaging.
Imaging should emphasize identification of all clinically
relevant sites of disease, including tumors large enough to
be serially assessed to determine response to therapy as well
as those that might require additional localized interven-
tion, such as surgery, external radiation therapy, radio-
frequency ablation, cryotherapy, cement injection, or embo-
lization. These treatments should be performed whenever
needed before the initiation of any systemic treatment, and
they may enable systemic treatment to be postponed in
some patients.
Diagnostic procedures in metastatic MTC patients should
include spiral computed tomographic scanning or magnetic
resonance imaging of the brain, ultrasonography of the
neck, contrast-enhanced spiral computed tomographic
scanning of the neck and chest, triple-phase computed
tomographic scanning or preferably magnetic resonance
imaging of the liver (because liver metastases may be
difficult to visualize with computed tomography during
anti-angiogenic treatment), bone scintigraphy and magnetic
resonance imaging of the spine and pelvis. Fluoro-
deoxyglucose (FDG) uptake on positron emission tomogra-
phy scanning is usually low, and for this reason FDG
positron emission tomography scanning is usually poorly
sensitive and cannot be used to assess progression rate or
response to treatment (1,3).
In the absence of treatment, imaging is repeated every six
months, and progression rate is assessed using Response
Evaluation Criteria in Solid Tumor (RECIST) (4,5). Patients
with measurable lesions and documented progression in a
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125given time interval (between 6 and 15 months) should be
considered candidates for systemic treatment. Progression
rate can also be evaluated by the doubling times of serum
markers, calcitonin and carcinoembryonic antigen levels
(6,7), but progression should always be confirmed by
imaging (4,5).
Standard Systemic Treatments
Symptomatic treatments of diarrhea include loperamide,
diphenoxylate/atropine, and codeine (1). Earlier clinical trials
of cytotoxic chemotherapiessuffered many shortcomings. Due
to both the rarity of apparent benefit and the significant
toxicity of the treatments, physicians enrolled only patients
with a large tumor burden and rapidly progressive metastatic
disease. The few prospective trials that were reported did not
include sufficient numbers of patients to demonstrate benefits
or reject false-negative conclusions. None used the now-
standard RECIST (4,5), and many trials reported results
mixing together patients with differentiated thyroid cancer,
MTC and anaplastic thyroid cancer. The most frequently
tested agent in thyroid cancer patients is doxorubicin, used
either alone or in combination with cisplatin. Tumor response
rates range from 0% to 22% in MTC patients, with all
responses being partial and only lasting a few months (8,9).
As MTC is a well-differentiated endocrine tumor, various
combinations of 59-fluorouracil, dacarbazine, streptozocin,
cyclophosphamide, and vincristine have been used and
produced some responses (in about 20% of patients) with
symptomatic improvement in some (10). Newer cytotoxic
drugs, such as taxanes, gemcitabine, or irinotecan, have not
been reported in significant series of MTC patients.
Treatment with bi-specific antibodies directed against
carcinoembryonic antigen and diethylene triamine pentaa-
cetic acid (DTPA) and with DTPA labeled with
13I or with
octreotide labeled with yttrium-90 prolonged overall survi-
val but did not induce objective responses in patients with
large metastases (11,12), and hematological and renal
toxicities were significant. Interferon a and somatostatin
analogs used either alone or in combination in MTC patients
only produced an inconstant and transient effect on
diarrhea. Dendritic cell immunotherapy may be effective
but is still under evaluation (13).
In conclusion, these therapeutic methods provide low
response rates in patients with advanced and progressive
refractory MTC.
Molecular Targeted Therapies
Several molecular abnormalities thought to be important
in thyroid oncogenesis and/or progression have been
defined in MTC and represent potential targets for therapy
(1,2,14). The aims of treatments are first to improve the
quality of life and second to prolong overall survival.
Because it is difficult to demonstrate an improvement in
overall survival in patients with slowly progressing disease
and a long life expectancy, surrogate parameters have been
used: the response rate studied in phase II trials is poorly
related to overall survival; progression-free survival studied
in randomized phase III trials is better related to overall
survival. At the present time, results of only one phase III
trial are available.
Molecular targets
In most familial forms of MTC, one of a variety of
germline RET (rearranged during transfection) mutations is
found. The proto-oncogene receptor RET is a membrane
receptor with tyrosine kinase activity, and these mutations
activate the kinase function that triggers downstream
mitogenic and survival signaling. Somatic mutations in
RET are also found in 30–50% of sporadic MTC tumors, and
of these, 80% are mutations at codon 918. Once activated,
RET stimulates several intracellular signaling cascades that
include the GTPase-Ras/serine/threonine-protein kinase B-
raf (BRAF)/mitogen-activated protein kinase (MAPK) and
the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/
alpha serine/threonine-protein kinase (AKT) pathways.
Besides RET, BRAF mutations have only been rarely
reported in MTC, but RAS mutations have been found in
68% of MTC tumors without RET mutation and rarely in
MTC harboring a RET mutation (15). Finally, little is known
about loss of function of tumor suppressors in MTC (1,2).
Angiogenesis serves a critical role in the development of
these hypervascularized tumors and provides another set of
potential molecular targets for therapy. Vascular endothelial
growth factors (VEGF) and VEGF receptors (VEGFR-1 (Flt-
1) and VEGFR-2 (Flk-1, KDR)) are often overexpressed in
thyroid cancer tissues, both in tumor cells and supporting
vascular endothelium, and they also trigger the MAPK
signaling pathway (17). Receptors for the fibroblast growth
factor and for the platelet-derived growth factor are also
often overexpressed and may play a role in tumor
angiogenesis.
Table 1 - Kinase inhibitor activities relevant to thyroid carcinomas.
Drug Inhibitory Concentration 50% (nm)
VEGFR1 VEGFR2 VEGFR3 RET BRAF Other targets
Axitinib 1.2 0.25 0.29
Sunitinib 2 9 17 41
Motesanib 2 3 6 59 PDGFR, CKIT
Sorafenib 90 20 49 6
Vandetanib 40 110 100 EGFR
Pazopanib 10 30 47 PDGFR, C-KIT
Cabozantinib (XL184) 0.035 4 C-MET, C-KIT
Lenvatinib (E7080) 22 4 5 35 PDGFR, FGFR
VEGFR1 = vascular endothelial growth factor 1, VEGFR2 = vascular endothelial growth factor 2, VEGFR3 = vascular endothelial growth factor 3, BRAF =
GTPase-Ras/serine/threonine-protein kinase B-raf.
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The RET kinase appears to be a promising target for
molecular therapy of MTC (2,14). ATP-competitive inhibitors
that exert an inhibitory effect on the RET kinase prevent the
activation of the downstream proteins (Table 1). Owing to the
close structural relationship between the kinases in RET and
VEGFR, most VEGFR kinases inhibitors also inhibit RET
kinase. For example, vandetanib effectively inhibits VEGFR2,
VEGFR3, epidermal growth factor receptor (EGFR) and RET
kinases. X-ray crystallographic analysis of the vandetanib-
RET kinase complex demonstrates that the drug docks into
theATP-bindingpocketofthekinase,inhibitingthe wild-type
enzyme and most of the activated mutant forms. Sorafenib,
sunitinib, motesanib, lenvatinib (E7080), and cabozantinib
(XL-184) are also multi-kinase inhibitors that share the ability
to inhibit RET and VEGFR, along with other kinases; in
contrast, axitinib and pazopanib seem to act only as anti-
VEGFR agents. C-met is overexpressed in medullary thyroid
cancer as a result of RET activation, and cabozantinib that
inhibits both RET and c-met is being tested in MTC (16,18).
Results of clinical trials
Available results in MTC (Table 2) patients from phase I,
II, and III trials have clearly confirmed the efficacy of these
compounds. To date only vandetanib has achieved US Food
and Drug Administration regulatory approval and more
recently European Medicines Agency approval for therapy
of advanced and progressive MTC, but some treatment
guidelines recommend use of available agents for selected
patients with progressive metastatic disease on the basis of
the phase II results (1,19).
Vandetanib at the maximal tolerated dose (300 mg/day)
included 30 patients with hereditary MTC who had germ-
line RET mutations. Partial response was observed in 10
patients, among whom six had a confirmed partial response,
and stable disease longer than 24 weeks was observed in
another 16 patients (20). Another phase II trial with
vandetanib (100 mg/day) included 19 hereditary MTC
patients, and a partial response was observed in three
patients and stable disease lasting 24 weeks or longer in a
further 10 patients, demonstrating anti-tumor activity in this
setting. However, it is not clear whether the lower dose
induced less toxicity, and two patients discontinued the
study because of a vandetanib-related adverse event (21).
A large randomized phase III trial comparing progression-
free survival (PFS) in patients treated with vandetanib
(300 mg/day) or placebo has been completed on 331 patients
withlocallyadvancedormetastaticMTC(22).ThemedianPFS
was significantly prolonged from 19.3 months in the placebo
arm to a predicted median of .30.5 months (median not yet
reached) in the vandetanib arm (Hazard Ratio 0.46; p,10
–4);
partial responses were observed in 45% of patients treated
with vandetanib, with a predicted median duration of
response of 22 months. Benefits of vandetanib treatment were
observed in all subgroups of patients, regardless of RET
mutation status, progression rate and tumor burden. Sufficient
events to analyze overall survival have not occurred yet. The
serum calcitonin and carcinoembryonic antigen levels
decreased by $50% and over a minimum of four weeks in
69% and 52% of patients, respectively. However, calcitonin
production by MTC is controlled by the RET signalling
pathway, and RET kinase inhibitors may decrease calcitonin
production independent of tumor mass changes (23). Time to
worsening of pain was significantly improved by vandetanib.
In some patients, diarrhea was improved rapidly after
initiation of therapy, and this often allowed patients to resume
a normal social life. Adverse events, including diarrhea,
fatigue, rash, hypertension, and prolongation of the QTc
interval on electrocardiogram, were mainly classified as grade
1 or 2. However, 12% of patients receiving vandetanib
discontinued treatment and 35% required that their dose of
vandetanib be reduced because of an adverse event.
Cabozantinib (XL-184). In a phase I trial, cabozantinib
induced a partial response in 17 of 34 evaluable MTC
patients, of whom 10 had a confirmed partial response, and
another 15 patients had stable disease (18). Partial responses
were observed regardless of RET mutation status, and in
both treatment-naı ¨ve patients and patients who had
previously been treated with kinase inhibitors, suggesting
that there is no cross resistance with other compounds. On
the basis of these favorable results, a randomized phase III
trial of cabozantinib (175 mg/day) versus placebo is
ongoing in patients with progressive MTC (NCT00704730).
Motesanib. In a phase II trial, motesanib (starting at
125 mg/day) induced a partial response in only two of 91
patients, but another 43% had stable disease longer than 24
weeks. The low efficacy of the drug may be attributed to its
malabsorption related to diarrhea (24).
Table 2 - Results obtained in patients with medullary thyroid carcinoma with kinase inhibitors.
Author Patients (n) PR (%)
SD .6
months (%)
Median PFS
(months)
Median OS
(months)
Dose reduction
for toxicity (%)
Withdrawal
for toxicity (%)
Vandetanib Wells (2010)
Robinson (2010)
Wells (2010)
30
19
331
30/20 c
16
44
53
NE
53
27.9
NE
30.5 (v) vs. 19.3
(placebo)
NE
10
.36
73
15
35
23
11
12
Cabozantinib Kurzrock (2010) 34 50/29 c 44
Motesanib Schlumberger (2009) 83 2 43 11 NE NE NE
Axitinib Cohen (2008) 11 18 27 17 .36 38 13
Sunitinib De Souza (2010)
Carr (2010)
25
6
32
50
46
33
NE
NE
NE
NE
NE
NE
Sorafenib Kober (2007)
Lam (2010)
5
19
40
10
aaa
43
aaa
17.9
aaa
NE
aaa
76
aaa
16
Pazopanib Bible (2010) 14 7 57
Imatinib DeGroot (2007)
Frank-Raue (2007)
15
9
0
0
27
56
27 20
PFS = progression-free survival, OS = overall survival, c = confirmed; NE = not evaluated.
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127Sorafenib. In a phase II trial, sorafenib (400 mg/twice
daily) induced a partial response in two of 21 patients, and
another nine patients had stable disease for more than 15
months; calcitonin levels decreased over 50% in nine
patients (25). In another trial with five MTC patients, two
had a partial response (26). A phase I trial of sorafenib
combined with the farnesyl transferase inhibitor tipifarnib
yielded partial response in five patients and stable disease
in another five patients, with a median PFS of 15 months
(27).
Axitinib. In a phase II trial, axitinib (5 mg twice daily)
induced a partial response in two of 11 patients and another
three patients had stable disease lasting at least 16 weeks
(28).
Sunitinib. In a phase II trial, sunitinib (50 mg/day, 4
weeks on and 2 weeks off) induced a partial response in
eight of 25 patients and another 46% had disease stabiliza-
tion for more than 24 weeks (29). In a smaller trial, sunitinib
(37.5 mg/day continuously) induced a partial response in
three of six patients (30).
Pazopanib. In a phase II trial, pazopanib (800 mg/day)
induced a partial response in one of 14 patients and another
eight patients had stable disease (31).
Lenvatinib (E7080). E7080 showed promising results in
several MTC patients in a phase I trial (32), and a phase II
trial in progressive MTC is ongoing (NCT00784303).
Imatinib. Imatinib was used in two trials (starting dose
600 mg/day) on nine and 15 MTC patients, respectively,
and no tumor response was observed (33,34). In a phase I
trial combining imatinib with dacarbazine and capecitabine,
no response was observed in seven MTC patients (35).
Toxicities of molecularly targeted therapies
Adverse effects from these targeted therapies are sig-
nificant, including fatigue, hypertension, QTc prolongation,
anorexia, diarrhea, cytopenias, and skin toxicities. These
short- or median-term side effects may lead to dose
reduction in 11–73% of patients and to withdrawal of drug
in 7–25%. Serum thyroid-stimulating hormone levels should
be regularly monitored as they may increase during
treatment with any of these kinase inhibitors; such an effect
should lead to an increase in the daily levothyroxine
treatment dose (36). Given that these treatment modalities
may be given for months or even years, further work to
minimize toxicities is needed.
CONCLUSION AND PERSPECTIVES
Although response criteria in contemporary trials differ
markedly from those in trials evaluating cytotoxic che-
motherapy, the anti-tumor efficacy of these agents in MTC
patients is likely to be much greater than that of earlier
chemotherapies. Benefits demonstrated with vandetanib in
improving PFS and delaying worsening of pain counter-
balance its adverse effects. Results of the ongoing phase III
trial with cabozantinib are also expected to confirm the
promising results obtained in the phase I trial. To date only
vandetanib has been labeled by the US Food and Drug
Administration for use in the rare MTC patients with a large
tumor burden in whom progression has been documented,
and it should be used as first-line treatment for this
indication. Patients in whom the use of vandetanib is
contraindicated or who experience toxicity or resistance
should preferably be included in prospective trials, and
even phase I trials that are testing the newest therapies
should be considered for patients with progressive thyroid
cancer, as these protocols may allow early identification of
possibly effective drugs (37).
The drugs used up to now have similar mechanisms of
action: all are anti-angiogenic and most also target the RET
kinase. The relative role of the inhibition of each target or of
their combined inhibition is currently unknown, but
because axitinib and pazopanib are thought not to inhibit
RET kinase, responses suggest an important role for the
anti-angiogenic effects of these compounds. Also, responses
to vandetanib or cabozantinib have been observed in
patients without RET mutation, probably indicating that
targeting mutant RET may not be necessary in all MTC
tumors.
Future progress will be made in three directions. Firstly,
by improving the knowledge of targets present in each
individual tumor and by increasing the number of drugs
directed against each of these targets, it may be possible to
offer thyroid cancer patients a personalized selection of
therapies. Secondly, there is an urgent need to test other
drugs in thyroid cancer patients and to understand the basis
of tumor response. Further trials should also search for
other treatment modalities, including combination with
cytotoxic chemotherapy or sequential treatment modalities
or immunotherapy (21). Finally, to increase the accrual of
patients, to optimize the experimental design of the
protocol, to improve the characterization of tumor tissues,
and to improve the tolerance of treatment, the collaborative
participation of a multidisciplinary team of endocrinolo-
gists, oncologists, nuclear physicians, surgeons, patholo-
gists, laboratory researchers, and statisticians should be
strongly encouraged through national and international
networks.
Search strategy: All papers written in English found on
PubMed between 2000 and 2010 using the key words
‘‘metastatic thyroid cancer, anaplastic thyroid cancer,
targeted therapies’’ were analyzed.
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